Active control cancer trials
Executive Summary
Design and analysis of active control trials added to the agenda for the Dec. 14 meeting of FDA's Oncologic Drugs Advisory Committee at the Holiday Inn in Bethesda, Md., beginning at 8:00 a.m. Review of Searle's Celebrex for the regression and prevention of adenomatous polyps which may lead to the development of colorectal cancer in patients with familial adenomatous polyposis will begin at approximately 10:00 a.m. The Dec. 13 agenda remains unchanged: Rhone-Poulenc Rorer's Taxotere for the new indication of metastatic non-small cell lung cancer and Ligand's Targretin for cutaneous T-cell lymphoma